Finanzwire Finanzwire
Basculer en Français
11103 Companies
244258 Keywords
172360 Articles
131631 Press releases
Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA Remove
  1. Home
  2. Companies
  3. ORPHAN SYNERGY EUROPE-PHARMA
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 05/22/2024 at 07:35, 2 years 4 months ago

    OSE Immunotherapeutics and Boehringer Ingelheim Expand Collaboration for Novel Treatments

    Collaboration Immunotherapy Cancer Cardio-renal-metabolic
  • PRESS RELEASE

    published on 05/22/2024 at 07:30, 2 years 4 months ago

    OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

    OSE Immunotherapeutics and Boehringer Ingelheim expand partnership to develop first-in-class therapies for cancer and cardio-renal-metabolic diseases, aiming to address unmet patient needs
    Partnership Cancer Boehringer Ingelheim OSE Immunotherapeutics First-in-class Treatments
    Logo of ORPHAN SYNERGY EUROPE-PHARMA
  • PRESS RELEASE

    published on 05/26/2023 at 08:15, 3 years 4 months ago

    OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23

    Logo of ORPHAN SYNERGY EUROPE-PHARMA
Previous page
1 ... 7 8
Accesswire
  • Published on 09/30/2026 at 23:30, 32 minutes ago

    Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.

  • Published on 09/30/2026 at 20:35, 3 hours 27 minutes ago

    Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited

  • Published on 09/30/2026 at 15:50, 8 hours 12 minutes ago

    Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans

  • Published on 09/30/2026 at 14:37, 9 hours 25 minutes ago

    NuRAN Leverages Starlink Backhaul to Drive Higher Revenue Per Rural Site

  • Published on 09/30/2026 at 14:31, 9 hours 31 minutes ago

    First Breach Expands Ammunition Manufacturing Operations to Seven Days a Week

View all ACCESSWIRE
EQS Group
  • Published on 09/30/2026 at 23:23, 38 minutes ago

    LM PAY S.A. publishes audited FY 2025 results: EBIT reaches PLN 12.4 million and exceeds preliminary result and guidance

  • Published on 09/30/2026 at 22:34, 1 hour 27 minutes ago

    The Change of Date of the Annual Report 2025 Publication

  • Published on 09/30/2026 at 22:05, 1 hour 56 minutes ago

    ADS-TEC Energy Reports First Half 2026 Results; Advances Gigawatt-Scale SKM Storage Project and Strengthens its Position to Scale Own & Operate Model

  • Published on 09/30/2026 at 22:05, 1 hour 56 minutes ago

    Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

  • Published on 09/30/2026 at 20:50, 3 hours 11 minutes ago

    EQS-Adhoc: Avemio AG: Adverse Audit Opinion on 2025 Consolidated Financial Statements and Group Management Report – 2025 Annual Report Published

View all EQS
Les Echos
  • Published on 09/30/2026 at 18:44, 5 hours 17 minutes ago

    Broadcast of the 5th edition of “On the way up”

  • Published on 09/30/2026 at 18:15, 5 hours 46 minutes ago

    The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026

  • Published on 09/30/2026 at 18:00, 6 hours 2 minutes ago

    Thales announces the distribution of an interim dividend

  • Published on 09/30/2026 at 18:00, 6 hours 2 minutes ago

    Cie du Bois Sauvage : Compagnie du Bois Sauvage increases its stake in Eaglestone to support its long-term development (Inside information)

  • Published on 09/30/2026 at 12:00, 12 hours 2 minutes ago

    Capital increase through exercise of subscription rights

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy